Literature DB >> 22578720

Clinical characteristics of heavy and non-heavy smokers with schizophrenia.

Heidi J Wehring1, Fang Liu, Robert P McMahon, Kristen M Mackowick, Raymond C Love, Lisa Dixon, Deanna L Kelly.   

Abstract

Up to 50-90% of persons with schizophrenia smoke cigarettes. Limited data and theories suggest persons with schizophrenia may smoke for different reasons than persons without schizophrenia, making smoking cessation interventions particularly challenging in this population. Although health consequences of smoking are widely known, less information is available regarding characteristics of different amounts of smoking exposure in this population. This study was performed to investigate differences between heavy (≥ 1 pack per day) and non-heavy (<1 pack per day) smoking in patients with schizophrenia. Data from 745 patients, mean age 41.3+/-12.6 years, were drawn from a population of smokers admitted to State of Maryland inpatient mental health facilities (1994-2000). Records were reviewed to obtain demographic information, diagnosis, medication, smoking and substance use. 43% of patients were characterized as heavy smokers. Heavy and non-heavy groups did not differ in age, GAF, weight, or BMI. No differences were found in race, gender or antipsychotic treatments. However, patients smoking ≥ 1 packs per day were more likely to use other substances such as alcohol (χ(2)=6.67, df=1, p=0.01), cocaine (χ(2)=6.66, df=1, p=0.01), and other substances (χ(2)=9.95, df=1, p=0.003) compared to non-heavy smokers. No differences in cannabis or heroin use were found by smoking category. Controlling for age, race, sex and BMI, heavy smokers had higher total cholesterol (190.7(51.6)mg/dL) compared to non-heavy smokers (178.2 (43.0)mg/dL, p=0.03), but no differences were found in glucose or blood pressure. Heavy smoking may be a particular health risk in schizophrenia and significant efforts for smoking cessation or reduction are needed.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22578720      PMCID: PMC4062915          DOI: 10.1016/j.schres.2012.03.024

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  59 in total

1.  Subjective and physiological responses to smoking cues in smokers with schizophrenia.

Authors:  Jennifer W Tidey; Damaris J Rohsenow; Gary B Kaplan; Robert M Swift
Journal:  Nicotine Tob Res       Date:  2005-06       Impact factor: 4.244

2.  Treatment of patients with substance use disorders, second edition. American Psychiatic Association.

Authors:  Herbert D Kleber; Roger D Weiss; Raymond F Anton; Bruce J Rounsaville; Tony P George; Eric C Strain; Shelly F Greenfield; Douglas M Ziedonis; Thomas R Kosten; Grace Hennessy; Charles P O'Brien; Hilary Smith Connery; John S McIntyre; Sara C Charles; Daniel J Anzia; James E Nininger; Ian A Cook; Paul Summergrad; Molly T Finnerty; Sherwyn M Woods; Bradley R Johnson; Joel Yager; Robert Pyles; Lawrence Lurie; C Deborah Cross; R Dale Walker; Roger Peele; Mary Ann Barnovitz; Sheila Hafter Gray; John P D Shemo; Sunil Saxena; Tina Tonnu; Robert Kunkle; Amy B Albert; Laura J Fochtmann; Claudia Hart; Darrel Regier
Journal:  Am J Psychiatry       Date:  2006-08       Impact factor: 18.112

3.  Treatment of comorbid tobacco use in people with serious mental illness.

Authors:  Katrina Lising-Enriquez; Tony P George
Journal:  J Psychiatry Neurosci       Date:  2009-05       Impact factor: 6.186

4.  Smoking initiation and schizophrenia: a replication study in a Chinese Han population.

Authors:  Xiang Yang Zhang; Cun Bao Li; Min Li; You Lan Zheng; Chong Xi Zhang; Quan Zhi Yan; Wen Zhong Liu; Yi Min Kang; Fan Wang; Da Chun Chen; Mei Hong Xiu; Thomas R Kosten
Journal:  Schizophr Res       Date:  2010-06       Impact factor: 4.939

Review 5.  A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia.

Authors:  Victoria C Wing; Caroline E Wass; Debra W Soh; Tony P George
Journal:  Ann N Y Acad Sci       Date:  2011-11-30       Impact factor: 5.691

6.  Predictors of pancreatic cancer mortality among a large cohort of United States adults.

Authors:  S S Coughlin; E E Calle; A V Patel; M J Thun
Journal:  Cancer Causes Control       Date:  2000-12       Impact factor: 2.506

7.  Tobacco use in schizophrenia: a study of cotinine concentrations in the saliva of patients and controls.

Authors:  Jan-Erik Strand; Henrik Nybäck
Journal:  Eur Psychiatry       Date:  2005-01       Impact factor: 5.361

8.  A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder.

Authors:  Amanda Baker; Robyn Richmond; Melanie Haile; Terry J Lewin; Vaughan J Carr; Rachel L Taylor; Sylvia Jansons; Kay Wilhelm
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

Review 9.  Tobacco smoking within psychiatric inpatient settings: biopsychosocial perspective.

Authors:  David Olivier; Dan I Lubman; Richard Fraser
Journal:  Aust N Z J Psychiatry       Date:  2007-07       Impact factor: 5.744

Review 10.  Health habits of patients with schizophrenia.

Authors:  Christiane Roick; Anita Fritz-Wieacker; Herbert Matschinger; Dirk Heider; Jana Schindler; Steffi Riedel-Heller; Matthias C Angermeyer
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-02-13       Impact factor: 4.519

View more
  9 in total

1.  Demographics, clinical characteristics and cognitive symptoms of heavy smokers and non-heavy smokers in Chinese male patients with chronic schizophrenia.

Authors:  Shuochi Wei; Dongmei Wang; Huixia Zhou; Luyao Xia; Yang Tian; Qilong Dai; Rongrong Zhu; Wenjia Wang; Dachun Chen; Meihong Xiu; Li Wang; Xiangyang Zhang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-04-26       Impact factor: 5.760

2.  Predictors of smoking cessation group treatment engagement among veterans with serious mental illness.

Authors:  Letitia E Travaglini; Lan Li; Clayton H Brown; Melanie E Bennett
Journal:  Addict Behav       Date:  2017-07-10       Impact factor: 3.913

3.  Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population.

Authors:  Xiang Yang Zhang; Da Chun Chen; Yun Long Tan; Mei Hong Xiu; Jingyi Cui; Li Hui; Fu De Yang; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2013-08-21       Impact factor: 4.530

Review 4.  nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

Authors:  Vinay Parikh; Munir Gunes Kutlu; Thomas J Gould
Journal:  Schizophr Res       Date:  2016-01-21       Impact factor: 4.939

5.  Attitudes about smoking cessation treatment, intention to quit, and cessation treatment utilization among young adult smokers with severe mental illnesses.

Authors:  Mary F Brunette; Joelle C Ferron; Kelly A Aschbrenner; Sarah I Pratt; Pamela Geiger; Samuel Kosydar
Journal:  Addict Behav       Date:  2018-09-25       Impact factor: 3.913

6.  Brief Arabic tobacco craving questionnaire: An investigation into craving and heavy smoking in Saudi Arabian males.

Authors:  Abdulaziz A Albrithen; Edward G Singleton
Journal:  J Family Community Med       Date:  2015 Jan-Apr

7.  Nicotine dependence in an isolated population of Kashubians from North Poland: a population survey.

Authors:  Alicja Sieminska; Ewa Jassem; Karolina Kita-Milczarska
Journal:  BMC Public Health       Date:  2015-02-04       Impact factor: 3.295

8.  Nicotine dependence in the mental disorders, relationship with clinical indicators, and the meaning for the user.

Authors:  Renata Marques de Oliveira; Antônio Carlos Siqueira Júnior; Jair Lício Ferreira Santos; Antonia Regina Ferreira Furegato
Journal:  Rev Lat Am Enfermagem       Date:  2014 Jul-Aug

9.  Characteristics of Chinese smokers with psychotic disorders and their predictors on smoking cessation in Hong Kong.

Authors:  Raymond K S Ho; Gina M T Lee; Patrick W Y Fok; Helen C H Chan; Joe K W Ching
Journal:  Tob Prev Cessat       Date:  2020-01-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.